Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC).

24 Jun 2013

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.

10 Jun 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Cancer Genetics introduces proprietary urogenital cancer array for diagnosing kidney cancer

Cancer Genetics, Inc., a leader in oncology-focused personalized medicine, has launched a proprietary urogenital cancer array, UroGenRA, intended for kidney cancer diagnosis and subtyping in its own laboratory.

3 May 2013

Researchers find that VEGF may not have any prognostic value for advanced prostate cancer

The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology.

30 Apr 2013

Laparoscopic radical nephropathy effective for advanced renal masses

Laparoscopic radical nephrectomy is an effective treatment approach for individuals with renal cell carcinoma who have larger or more advanced renal masses, report researchers.

29 Apr 2013

Study reveals a new way for detecting colorectal cancers

A unique new study led by University of Kentucky Markey Cancer Center researchers Guo-Min Li and Libya Gu, in collaboration with Dr. Wei Yang at National Institutes of Health, reveals a novel mechanism explaining the previously unknown root cause of some forms of colorectal cancers.

26 Apr 2013

Study shows chemical shift MRI can help differentiate clear cell renal carcinoma from other renal cancer

Adding "chemical shift" techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.

19 Apr 2013

Study results show trends in surgical management of patients with kidney disease

Researchers at the University of California, San Diego School of Medicine have released study results that show national treatment trends in the surgical management of patients with kidney disease.

26 Mar 2013

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor, or TKI, that is being investigated for use in patients with advanced renal cell carcinoma (RCC), or kidney cancer.

19 Mar 2013

Study reveals potential markers for treating patients with metastatic clear cell RCC

Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study to be presented at the 28th Annual EAU Congress currently on-going in Milan.

18 Mar 2013

New immunoassay appears to be valid screening method for early detection of renal cell carcinoma

A new immunoassay that tests for the presence of three biomarkers appears to be a valid screening method for the early detection of malignant kidney cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

11 Mar 2013

FDA's Oncologic Drugs Advisory Committee to review NDA for tivozanib

AVEO Oncology and Astellas Pharma Global Development, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee will review the company's New Drug Application for tivozanib for the treatment of patients with advanced renal cell carcinoma during the morning session of its meeting on May 2, 2013.

27 Feb 2013

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Cancer Genetics introduces proprietary urogenital cancer array for diagnosing kidney cancer

Researchers find that VEGF may not have any prognostic value for advanced prostate cancer

Laparoscopic radical nephropathy effective for advanced renal masses

Study reveals a new way for detecting colorectal cancers

Study shows chemical shift MRI can help differentiate clear cell renal carcinoma from other renal cancer

Study results show trends in surgical management of patients with kidney disease

Tivozanib: an interview with Stephen L. Eck, M.D., Ph.D., Vice President, Global Oncology, Astellas Pharma US, Inc. Global Development

Study reveals potential markers for treating patients with metastatic clear cell RCC

New immunoassay appears to be valid screening method for early detection of renal cell carcinoma

FDA's Oncologic Drugs Advisory Committee to review NDA for tivozanib

Gene mutation findings classify renal cell carcinoma

Consortium database model compares favorably for RCC prognosis

COX-2 inhibitor extends sunitinib activity in renal cell carcinoma

Metastatic tumors best for sunitinib response evaluation in mRCC

Possible alternative to biopsy discovered for renal cancer diagnosis

Your complete guide to renal proximal tubule cells eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Your complete guide to renal proximal tubule cells eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in